Latest Sanofi Press Releases and News | Sanofi
WEBSep 20, 2024 · Stay informed with the latest Sanofi press releases and news updates. Discover new developments in healthcare and pharmaceuticals with Sanofi.
Sanofi pushes ahead with €20bn consumer healthcare spin-off
WEBJun 2, 2024 · The move makes Sanofi the latest Big Pharma company to seek to separate low-margin, consumer businesses from divisions focused on innovative new medicines that offer higher returns.
Sanofi US News
WEBSep 27, 2024 · Sanofi and Regeneron are motivated to transform the treatment paradigm of COPD by examining the role different types of inflammation play in the disease progression through Dupixent, a first-in-class biologic, and the investigation of itepekimab.
Sanofi Pipeline Transformation to Accelerate Growth Driven by …
WEBDec 7, 2002 · Sanofi’s R&D will lead to a 50% increase in the number of Phase 3 studies between 2023 and 2025, creating the greatest pipeline momentum in Sanofi’s history. The company’s commitment to R&D will also support an expected 25 mid- to late-stage read-outs and up to 19 regulatory submissions for its pharma assets in the next two years.
Sanofi Enters Next Chapter of Play to Win Strategy | Sanofi
WEBOct 27, 2005 · Sanofi today provided a comprehensive update regarding its Play to Win strategy. This strategy continues to focus on the critical goals of executing transformative medicine and vaccines launches, driving agile and efficient resource deployment and enhancing R&D productivity.
Press Room - Sanofi US News
WEBApr 26, 2024 · New data presented at ATS demonstrate Sanofi’s leadership in advancing potential new therapies for patients with immune-mediated respiratory diseases. Late-breaking data from the landmark NOTUS and BOREAS phase 3 studies support Dupixent’s role as a potential first-in-class biologic treatment for certain adult patients with uncontrolled ...
Press Room - Sanofi US News
WEBSep 27, 2024 · Sanofi shipping BEYFORTUS® in US to help protect babies against RSV disease; new manufacturing line approved by FDA. Read more. Sep 13, 2024.
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEBSanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...
Sanofi Q4 earnings hit by weak dollar, generic competition
WEBFeb 1 (Reuters) - Sanofi's (SASY.PA) fourth-quarter operating income fell 5% as a weaker U.S. dollar and cheap competition to multiple sclerosis drug Aubagio outweighed rising sales of anti ...
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
WEB5 days ago · SNY. (Bloomberg) -- Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of ...